^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | cyclophosphamide (Alkylating agent) + thiotepa (DNA synthesis inhibitor, Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study
Excerpt:
885 patients (64% 4-9 ALN, 36% >9 ALN; 53% ER+/HER2-, 23% HER2+, 16% TN, 8% unknown) were randomized to FEC (n = 443) or HDCT (n = 442)….Long-term follow-up confirms survival benefit of HDCT in BC patients with >9 involved ALN and suggests benefit in TNBC patients.
DOI:
10.1093/annonc/mdy270.184
Trial ID:
